CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho

Cancer Research and Treatment. 2015;47(2):266-273. Published online 2014 August 29 DOI: https://doi.org/10.4143/crt.2013.158

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer

Jae Yun Lim, Jang Ho Cho, Se Joon Lee, Dong Ki Lee, Dong Sup Yoon, Jae Yong Cho

Cancer Research and Treatment. 2014;47(2):266-273

Link1

Link2 Link3

RM-028 Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer

P. Khatri, P. Kumari, S. Beniwal, S. Samdariya

Annals of Oncology. 2016;27:ii92

Link1 Link2 Link3

A Pilot Trial of Gemcitabine in Combination with Capecitabine or Erlotinib Compared to Gemcitabine alone in Patients with advanced Pancreatic Cancer

J.Y. Cho, J.Y. Lim, S.J. Lee, D.K. Lee, J.S. Park, D.S. Yoon, Y.H. Min

Annals of Oncology. 2012;23:ix240

Link1 Link2

Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study

E. Francois, J. Bennouna, E. Chamorey, M.C. Etienne-Grimaldi, N. Renée, H. Senellart, C. Michel, P. Follana, V. Mari, J.Y. Douillard, G. Milano

Chemotherapy. 2012;58(5):371-380

Link1 Link2 Link3

769 PUBLICATION Activity and tolerability of combination: capecitabine(c) plus gemcitabine(g) as first-line treatment in patients(pts) with locally advanced/metastatic pancreatic cancer

European Journal of Cancer Supplements. 2005;3(2):219-220

Link1 Link2

735 POSTER Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer

European Journal of Cancer Supplements. 2005;3(2):209

Link1 Link2

Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study

Roberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Daniele Marrelli, Franco Roviello, Edoardo Francini

Cancer Chemotherapy and Pharmacology. 2015;75(4):683-690

Link1

Link2 Link3

An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial

Cesare Gridelli, Charles Butts, Fortunato Ciardiello, Ronald Feld, Ciro Gallo, Francesco Perrone

Clinical Lung Cancer. 2008;9(4):235-238

Link1 Link2

PS11 Best of ECCO 13 Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer

European Journal of Cancer Supplements. 2005;3(4):12

Link1 Link2

P-0108 Docetaxel-Carboplatin for Patients with Advanced Pancreatic Cancer Progressing after Gemcitabine-Based Chemotherapy Followed by Metronomic Capecitabine

Ehab Shaltout, Eman Abd El Razek, Ahmed El-Gamal

Annals of Oncology. 2012;23:iv62

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.